Journal: Journal of Cancer Research and Clinical Oncology

Article Title: High PER1 expression is associated with STK11 mutation and clinical biomarkers of immunotherapy resistance in lung adenocarcinoma

doi: 10.1007/s00432-025-06269-9

Figure Lengend Snippet: PER1 expression is increased with loss of LKB1. A PER1 mRNA expression in control (C), sh STK11 (L), KRAS G12V (K), and KRAS G12V /sh STK11 (KL) invading HBEC3-KT organoids; notated with adjusted p-values from ordinary one-way ANOVA followed by Šídák's multiple comparisons tests, C vs L p < 0.0001, K vs KL p < 0.0001, L vs KL p = 0.0052. B PER1 mRNA expression in LKB1-wildtype (WT) and LKB1-knockout (KO) HBEC3-KT cells; two-tailed Student’s t-test, p < 0.0001. C Western blot of PER1, LKB1, pAMPK T172, AMPK, and Actin in LKB1-WT and LKB1-KO HBEC3-KT cells, with and without glucose. D Western blot of PER1, LKB1, and Lamin A/C in LKB1-WT and LKB1-KO HBEC3-KT cells. E Western blot of PER1, LKB1, and Actin in K and KL HBEC3-KT cells. F Western blot of PER1, LKB1, and Actin in empty-vector control A549 cells and with addback of wildtype LKB1. G PER1 mRNA expression in KRAS -mutant (K) and KRAS / STK11 -mutant (KL) tumors from the TCGA LUAD study; two-tailed Student’s t-test, p = 0.0224. H) PER1 protein abundance ratio in KRAS -mutant (K) and KRAS / STK11 -mutant (KL) tumors from the CPTAC 2020 study; two-tailed Student’s t-test, p = 0.0191. I) PER1 mRNA expression in LKB1-wildtype (WT) and LKB1-mutant (MUT) tumors from the TCGA LUAD study; two-tailed Student’s t-test, p < 0.0001. J) PER1 protein abundance ratio in LKB1-wildtype (WT) and LKB1-mutant (MUT) tumors from the CPTAC 2020 study; two-tailed Student’s t-test, p = 0.0422

Article Snippet: The following primary antibodies were diluted in 5% BSA in tris-buffered saline (Cell Signaling, 12498S) supplemented with 0.01% Tween-20 (TBS-T; ChemCruz, sc-29113B) and used at the indicated dilutions: PER1 (1:1000, Boster Bio, A00876, RRID:AB_3086701), LKB1 (1:1000, Cell Signaling, #3050, RRID:AB_823559), JAG1 (1:1000, Cell Signaling, #70,109, RRID:AB_2799774), pAMPK-T172 (1:1000, Cell Signaling, #2535, RRID:AB_331250), AMPK (1:1000, Cell Signaling, #2532, RRID:AB_330331), Actin (1:500, DSHB, JLA20, RRID:AB_528068; 1:1000, Sigma-Aldrich, A5441, RRID:AB_476744), Lamin A/C (1:1000, DSHB, MANLAC3(4C10), RRID:AB_2618205).

Techniques: Expressing, Control, Knock-Out, Two Tailed Test, Western Blot, Plasmid Preparation, Mutagenesis, Quantitative Proteomics

Journal: Journal of Cancer Research and Clinical Oncology

Article Title: High PER1 expression is associated with STK11 mutation and clinical biomarkers of immunotherapy resistance in lung adenocarcinoma

doi: 10.1007/s00432-025-06269-9

Figure Lengend Snippet: PER1 knockdown decreases proliferation of cells lacking LKB1. A Left, CCK-8 cell proliferation assay in KRAS G12V (K) and KRAS G12V /sh STK11 (KL) HBEC3-KT cells treated with siRNA for non-targeting control (NTC) and PER1 (si PER1 ). Right, Alternate presentation of the same growth curves, showing K and KL separately. B Statistical analysis of growth curves from A, showing the effect of si PER1 versus siNTC on cell proliferation of K (two-tailed Student’s t-test, p = 0.7547) and KL (two-tailed Student’s t-test, p = 0.0002) HBEC3-KT cells at 96 h. C Cell counting cell proliferation assay of siNTC- and si PER1 -treated KL HBEC3-KT cells; two-tailed Student’s t-test with correction for multiple comparisons, p = 0.035 at 48 h and p = 0.008 at 72 h. D Cell counting cell proliferation assay of siNTC- and si Per1 -treated JK-43-M cells; two-tailed Student’s t-test with correction for multiple comparisons, p = 0.0001 at 48 h and p = 0.0051 at 72 h. E Effect of siPER1 versus siNTC on relative cell number of A549 cells at 96 h; two-tailed Student’s t-test, p = 0.0263

Article Snippet: The following primary antibodies were diluted in 5% BSA in tris-buffered saline (Cell Signaling, 12498S) supplemented with 0.01% Tween-20 (TBS-T; ChemCruz, sc-29113B) and used at the indicated dilutions: PER1 (1:1000, Boster Bio, A00876, RRID:AB_3086701), LKB1 (1:1000, Cell Signaling, #3050, RRID:AB_823559), JAG1 (1:1000, Cell Signaling, #70,109, RRID:AB_2799774), pAMPK-T172 (1:1000, Cell Signaling, #2535, RRID:AB_331250), AMPK (1:1000, Cell Signaling, #2532, RRID:AB_330331), Actin (1:500, DSHB, JLA20, RRID:AB_528068; 1:1000, Sigma-Aldrich, A5441, RRID:AB_476744), Lamin A/C (1:1000, DSHB, MANLAC3(4C10), RRID:AB_2618205).

Techniques: Knockdown, CCK-8 Assay, Proliferation Assay, Control, Two Tailed Test, Cell Counting

Journal: Journal of Cancer Research and Clinical Oncology

Article Title: High PER1 expression is associated with STK11 mutation and clinical biomarkers of immunotherapy resistance in lung adenocarcinoma

doi: 10.1007/s00432-025-06269-9

Figure Lengend Snippet: PER1 knockdown decreases invasion in low-LKB1 H1299 leader cells. A Western blot of PER1, LKB1, JAG1, and Actin in Parental, Leader, and Follower H1299 cells. B Western blot PER1, LKB1, JAG1, Lamin A/C, and Tubulin in cytosolic (cyto) and nuclear (nuc) subcellular fractionation lysates from Parental (P), Leader (L), and Follower (F) H1299 cells. C Left, STK11 mRNA expression in Parental, Leader, and Follower H1299 cells; one-way ANOVA with multiple comparisons tests, Parental vs Leader p = 0.0133, Parental vs Follower p = 0.0512, Leader vs Follower p = 0.0008. Right, PER1 mRNA expression in Parental, Leader, and Follower H1299 cells; one-way ANOVA with multiple comparisons tests, Parental vs Leader p = 0.0852, Parental vs Follower p = 0.0080, Leader vs Follower p = 0.0007. D Effect of si PER1 versus siNTC on 48 h 3D invasion of Leader and Follower H1299 spheroids (n = 11–12); 2-way ANOVA with multiple comparisons, Leaders p < 0.0001, Followers p = 0.4328. E Representative images from H1299 spheroid invasion assays. Green lines indicate the spheroid cores and pink lines indicate the invasive edges

Article Snippet: The following primary antibodies were diluted in 5% BSA in tris-buffered saline (Cell Signaling, 12498S) supplemented with 0.01% Tween-20 (TBS-T; ChemCruz, sc-29113B) and used at the indicated dilutions: PER1 (1:1000, Boster Bio, A00876, RRID:AB_3086701), LKB1 (1:1000, Cell Signaling, #3050, RRID:AB_823559), JAG1 (1:1000, Cell Signaling, #70,109, RRID:AB_2799774), pAMPK-T172 (1:1000, Cell Signaling, #2535, RRID:AB_331250), AMPK (1:1000, Cell Signaling, #2532, RRID:AB_330331), Actin (1:500, DSHB, JLA20, RRID:AB_528068; 1:1000, Sigma-Aldrich, A5441, RRID:AB_476744), Lamin A/C (1:1000, DSHB, MANLAC3(4C10), RRID:AB_2618205).

Techniques: Knockdown, Western Blot, Fractionation, Expressing

Journal: Journal of Cancer Research and Clinical Oncology

Article Title: High PER1 expression is associated with STK11 mutation and clinical biomarkers of immunotherapy resistance in lung adenocarcinoma

doi: 10.1007/s00432-025-06269-9

Figure Lengend Snippet: Clinical significance of high PER1 expression in lung adenocarcinoma. A–B Top ten most differentially altered genes between the highest and lowest PER1 mRNA expression quartiles of lung adenocarcinoma samples in the TCGA LUAD study. C–D Top ten most differentially altered genes between the highest and lowest PER1 protein expression quartiles of lung adenocarcinoma samples in the CPTAC 2020 study. E Ragnum (p < 10 −10 , q < 10 −10 ), Buffa (p < 10 −10 , q < 10 −10 ), and Winter (p < 10 −10 , q = 1.06 −10 ) hypoxia scores as calculated in cBioPortal in Low PER1 versus High PER1 mRNA expression quartiles in the TCGA LUAD study. F Expression of SLC2A1 (GLUT1) in: Low PER1 and High PER1 expression quartiles in the TCGA LUAD study (two-tailed Student’s t-test, p < 0.0001), Low PER1 and High PER1 expression quartiles in the CPTAC-GDC study (two-tailed Student’s t-test, p = 0.0006), and Low PER1 and High PER1 expression quartiles in the CPTAC 2020 study (two-tailed Student’s t-test, p = 0.2034). G Expression of ANLN in: Low PER1 and High PER1 expression quartiles in the TCGA LUAD study (two-tailed Student’s t-test, p < 0.0001), Low PER1 and High PER1 expression quartiles in the CPTAC-GDC study (two-tailed Student’s t-test, p = 0.0006), and Low PER1 and High PER1 expression quartiles in the CPTAC 2020 study (two-tailed Student’s t-test, p = 0.0114). H Expression of HIF3A in: Low PER1 and High PER1 expression quartiles in the TCGA LUAD study (two-tailed Student’s t-test, p < 0.0001), Low PER1 and High PER1 expression quartiles in the CPTAC-GDC study (two-tailed Student’s t-test, p = 0.0049), and Low PER1 and High PER1 expression quartiles in the CPTAC 2020 study (two-tailed Student’s t-test, p = 0.0590). I Overall (p = 2.76 −4 , q = 0.0146), stromal (p = 2.001 −3 , q = 0.0323), and immune (p = 2.73 −3 , q = 0.0323) ESTIMATE scores as calculated in cBioPortal in Low PER1 versus High PER1 protein expression quartiles in the CPTAC 2020 study. J CD274 (PD-L1) mRNA expression in Low PER1 versus High PER1 expression quartiles in the TCGA LUAD study; two-tailed Student’s t-test, p = 0.0126. K CD274 (PD-L1) mRNA expression in Low PER1 versus High PER1 mRNA expression quartiles in the CPTAC GDC study; two-tailed Student’s t-test, p = 0.0005. L CD274 mRNA expression in Low PER1 versus High PER1 protein expression quartiles in the CPTAC 2020 study; two-tailed Student’s t-test, p = 0.0139. M) PD-L1 protein expression (as measured by protein abundance ratio) in the Low PER1 and High PER1 protein expression quartiles of the CPTAC 2020 study; two-tailed Student’s t-test, p = 0.0386

Article Snippet: The following primary antibodies were diluted in 5% BSA in tris-buffered saline (Cell Signaling, 12498S) supplemented with 0.01% Tween-20 (TBS-T; ChemCruz, sc-29113B) and used at the indicated dilutions: PER1 (1:1000, Boster Bio, A00876, RRID:AB_3086701), LKB1 (1:1000, Cell Signaling, #3050, RRID:AB_823559), JAG1 (1:1000, Cell Signaling, #70,109, RRID:AB_2799774), pAMPK-T172 (1:1000, Cell Signaling, #2535, RRID:AB_331250), AMPK (1:1000, Cell Signaling, #2532, RRID:AB_330331), Actin (1:500, DSHB, JLA20, RRID:AB_528068; 1:1000, Sigma-Aldrich, A5441, RRID:AB_476744), Lamin A/C (1:1000, DSHB, MANLAC3(4C10), RRID:AB_2618205).

Techniques: Expressing, Two Tailed Test, Quantitative Proteomics

Journal: Journal of Arrhythmia

Article Title: An uncommon ECG manifestation of normal pacemaker function

doi: 10.1002/joa3.12258

Figure Lengend Snippet: ECG with pacemaker enhancement algorithm turned on during the use of the closed loop stimulation algorithm

Article Snippet: One such example is the closed loop stimulation sensor unique to Biotronik (Biotronik GmbH) pacemakers.

Techniques:

Journal:

Article Title: Inappropriate Shock Delivery and Biventricular Pacing Cardiac Defibrillators

doi:

Figure Lengend Snippet: Fig. 1 Patient 1. Electrogram from the event leading to inappropriate shock delivery: atrial channel (top line), ventricular channel (middle line), and marker channel (bottom line). Atrial tachycardia occurs with atrial events falling within the postventricular atrial refractory period. Inherent ventricular activity emerges with double counting of ventricular electrical activity that meets the rate detection criteria for ventricular fibrillation. With defibrillation, the atrial tachycardia is aborted and biventricular pacing resumes; the QRS narrows and the ventricular double counting resolves.

Article Snippet: A biventricular pacing cardiac defibrillator (GEM® III AT, Medtronic, Inc.) was implanted.

Techniques: Marker, Activity Assay

Journal:

Article Title: Inappropriate Shock Delivery and Biventricular Pacing Cardiac Defibrillators

doi:

Figure Lengend Snippet: Fig. 3 Patient 3. A) Electrogram from the event leading to inappropriate shock therapy: atrial channel (top line), ventricular channel (middle line), and marker channel (bottom line). Ventricular tachycardia occurs with a cycle length of approximately 340 msec. No double counting occurs with this morphology of the ventricular tachycardia. B) Electrogram from the event leading to inappropriate shock delivery: atrial channel (top line), ventricular channel (middle line), and marker channel (bottom line). The morphology of the ventricular tachycardia has changed, although it still has a cycle length of approximately 340 msec. The double counting fulfills ventricular fibrillation detection criteria and leads to inappropriate shock delivery. The shock results in resumption of normal atrial and biventricular pacing with cessation of double counting.

Article Snippet: A biventricular pacing cardiac defibrillator (GEM® III AT, Medtronic, Inc.) was implanted.

Techniques: Marker